Open access

Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study

Hisashi Yamanaka, Shigenori Tamaki, Yumiko Ide, Hyeteko Kim, Kouichi Inoue, Masayuki Sugimoto, Yuji Hidaka, Atsuo Taniguchi, Shin Fujimori, Tetsuya Yamamoto, Hisashi Yamanaka, Shigenori Tamaki, Yumiko Ide, Hyeteko Kim, Kouichi Inoue, Masayuki Sugimoto, Yuji Hidaka, Mitsuko Akimoto, Naomi Ichikawa, Akira Sagawa, Hisayoshi Hirota, Tsuneo Tanaka, Hiroaki Jin, Ichiro Koni, Yasuharu Momoi, Soitiro Inoue, Tomomasa Izumiyama, Hideyuki Yagi, Hiroshi Tsutani, Masayuki Hakoda, Tomonori Ishii, Hiroshi Nakashima, Aizan Hirai

10.1136/annrheumdis-2017-211574

November 4, 2017

Development of a consensus core dataset in juvenile dermatomyositis for clinical use to inform research

Liza J McCann, Clarissa A Pilkington, Adam M Huber, Angelo Ravelli, Duncan Appelbe, Jamie J Kirkham, Paula R Williamson, Amita Aggarwal, Lisa Christopher-Stine, Tamas Constantin, Brian M Feldman, Ingrid Lundberg, Sue Maillard, Pernille Mathiesen, Ruth Murphy, Lauren M Pachman, Ann M Reed, Lisa G Rider, Annet van Royen-Kerkof, Ricardo Russo, Stefan Spinty, Lucy R Wedderburn, Michael W Beresford

10.1136/annrheumdis-2017-212141

October 30, 2017

Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)

Dinesh Khanna, Christopher P Denton, Celia JF Lin, Jacob M van Laar, Tracy M Frech, Marina E Anderson, Murray Baron, Lorinda Chung, Gerhard Fierlbeck, Santhanam Lakshminarayanan, Yannick Allanore, Janet E Pope, Gabriela Riemekasten, Virginia Steen, Ulf Müller-Ladner, Helen Spotswood, Laura Burke, Jeffrey Siegel, Angelika Jahreis, Daniel E Furst

10.1136/annrheumdis-2017-211682

October 24, 2017

Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study

Josef S Smolen, Jung-Yoon Choe, Nenad Prodanovic, Jaroslaw Niebrzydowski, Ivan Staykov, Eva Dokoupilova, Asta Baranauskaite, Roman Yatsyshyn, Mevludin Mekic, Wieslawa Porawska, Hana Ciferska, Krystyna Jedrychowicz-Rosiak, Agnieszka Zielinska, Younju Lee, Young Hee Rho

10.1136/annrheumdis-2017-211741

October 17, 2017